These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Vaccination with parenteral toxoid B protects hamsters against lethal challenge with toxin A-negative, toxin B-positive clostridium difficile but does not prevent colonization. Siddiqui F; O'Connor JR; Nagaro K; Cheknis A; Sambol SP; Vedantam G; Gerding DN; Johnson S J Infect Dis; 2012 Jan; 205(1):128-33. PubMed ID: 22124129 [TBL] [Abstract][Full Text] [Related]
3. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Weiss K Int J Antimicrob Agents; 2009 Jan; 33(1):4-7. PubMed ID: 18804351 [TBL] [Abstract][Full Text] [Related]
4. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. Geric B; Carman RJ; Rupnik M; Genheimer CW; Sambol SP; Lyerly DM; Gerding DN; Johnson S J Infect Dis; 2006 Apr; 193(8):1143-50. PubMed ID: 16544255 [TBL] [Abstract][Full Text] [Related]
5. Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties. Barker RH; Dagher R; Davidson DM; Marquis JK Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1525-34. PubMed ID: 17206941 [TBL] [Abstract][Full Text] [Related]
6. Co-infection of hamsters with toxin A or toxin B-deficient Clostridium difficile strains. Szczesny A; Martirosian G; Cohen S; Silva J Pol J Microbiol; 2005; 54(4):301-4. PubMed ID: 16599301 [TBL] [Abstract][Full Text] [Related]
7. Clostridium difficile and the disease it causes. Norén T Methods Mol Biol; 2010; 646():9-35. PubMed ID: 20597000 [TBL] [Abstract][Full Text] [Related]
8. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Babcock GJ; Broering TJ; Hernandez HJ; Mandell RB; Donahue K; Boatright N; Stack AM; Lowy I; Graziano R; Molrine D; Ambrosino DM; Thomas WD Infect Immun; 2006 Nov; 74(11):6339-47. PubMed ID: 16966409 [TBL] [Abstract][Full Text] [Related]
9. Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile. Hinkson PL; Dinardo C; DeCiero D; Klinger JD; Barker RH Antimicrob Agents Chemother; 2008 Jun; 52(6):2190-5. PubMed ID: 18391047 [TBL] [Abstract][Full Text] [Related]
10. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Louie TJ; Peppe J; Watt CK; Johnson D; Mohammed R; Dow G; Weiss K; Simon S; John JF; Garber G; Chasan-Taber S; Davidson DM; Clin Infect Dis; 2006 Aug; 43(4):411-20. PubMed ID: 16838228 [TBL] [Abstract][Full Text] [Related]
11. Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection. Baines SD; Freeman J; Wilcox MH Antimicrob Agents Chemother; 2009 May; 53(5):2202-4. PubMed ID: 19223641 [TBL] [Abstract][Full Text] [Related]
13. Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Braunlin W; Xu Q; Hook P; Fitzpatrick R; Klinger JD; Burrier R; Kurtz CB Biophys J; 2004 Jul; 87(1):534-9. PubMed ID: 15240486 [TBL] [Abstract][Full Text] [Related]
14. The role of toxin A and toxin B in Clostridium difficile infection. Kuehne SA; Cartman ST; Heap JT; Kelly ML; Cockayne A; Minton NP Nature; 2010 Oct; 467(7316):711-3. PubMed ID: 20844489 [TBL] [Abstract][Full Text] [Related]
15. Analysis of the physicochemical interactions between Clostridium difficile toxins and cholestyramine using liquid chromatography with post-column derivatization. Palace GP; Lazari P; Norton K Biochim Biophys Acta; 2001 Mar; 1546(1):171-84. PubMed ID: 11257520 [TBL] [Abstract][Full Text] [Related]
16. A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model. Anosova NG; Cole LE; Li L; Zhang J; Brown AM; Mundle S; Zhang J; Ray S; Ma F; Garrone P; Bertraminelli N; Kleanthous H; Anderson SF Clin Vaccine Immunol; 2015 Jul; 22(7):711-25. PubMed ID: 25924765 [TBL] [Abstract][Full Text] [Related]
17. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection. Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701 [TBL] [Abstract][Full Text] [Related]
18. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model. Freeman J; Marquis M; Crowther GS; Todhunter SL; Fawley WN; Chilton CH; Moeck G; Lehoux D; Wilcox MH J Antimicrob Chemother; 2012 Dec; 67(12):2919-26. PubMed ID: 22899803 [TBL] [Abstract][Full Text] [Related]
19. Therapy of Clostridium difficile in pseudomembranous and antibiotic-associated colitis. Panichi G Chemioterapia; 1987 Jun; 6(2 Suppl):493-4. PubMed ID: 2978388 [No Abstract] [Full Text] [Related]
20. Clostridial toxins: sensing a target in a hostile gut environment. Oezguen N; Power TD; Urvil P; Feng H; Pothoulakis C; Stamler JS; Braun W; Savidge TC Gut Microbes; 2012; 3(1):35-41. PubMed ID: 22356854 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]